A hydrocarbon-stapled BH3 helix peptide activated the apoptotic pathway in live mice, achieving tumor reduction — demonstrating that stapled peptides can work as cancer drugs in vivo for the first time.
Key findingA hydrocarbon-stapled BH3 alpha-helix peptide activated apoptosis in vivo in a mouse leukemia model, producing tumor reduction — the first demonstrati
What the researchers found
A hydrocarbon-stapled BH3 alpha-helix peptide activated apoptosis in vivo in a mouse leukemia model, producing tumor reduction — the first demonstration that stapled peptide technology achieves in-vivo anticancer efficacy through intracellular target engagement.
Why it matters
Relevant for cyclic-peptides, cancer, peptide-design.
How the study worked
animal-study study on cyclic-peptides, cancer.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
Science (New York, N.Y.), 305(5689), 1466-70
Citation
Walensky, Loren D; Kung, Andrew L; Escher, Iris; Malia, Thomas J; Barbuto, Scott; Wright, Renee D; Wagner, Gerhard; Verdine, Gregory L; Korsmeyer, Stanley J. (2004). Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.. Science (New York, N.Y.), 305(5689), 1466-70.